Search Results
Your search for ,had matches 18497 pages
Showing 17551 - 17600Adding Ziv-Aflibercept to Topotecan Improves Progression-Free Survival but Increases Toxicity in Platinum-Treated Small Cell Lung Cancer
The phase II Southwest Oncology Group (SWOG) S0802 trial reported in the Journal of Clinical Oncology by Allen et al showed that adding ziv-aflibercept (Zaltrap) to topotecan improved 3-month progression-free survival, but increased toxicity and had no effect on overall survival, in patients...
Total-Body Photography and Sequential Digital Dermoscopy Assist in Early Diagnosis of Primary Melanoma in High-Risk Individuals
In a study intended to help define optimal screening in individuals at high risk of melanoma, Moloney et al evaluated use of full-body examinations every 6 months along with dermoscopy and total-body photography for all patients and sequential digital dermoscopy imaging as indicated. The study,...
Study Identifies Novel Genomic Changes in Lung Adenocarcinoma
Researchers from Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and other centers have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer. Knowledge of these mutations could potentially identify a...
Study Identifies Irinotecan Dosing Levels Based on UGT1A1 Genotype
Risk of severe irinotecan-associated neutropenia is related in part to presence of the UGT1A1*28 variant, which is linked to reduced elimination of the irinotecan active metabolite SN-38. In a study reported in the Journal of Clinical Oncology, Innocenti et al identified appropriate irinotecan...
High-Dose Melphalan Plus Autologous Stem Cell Transplantation as Consolidation Shows Benefit in Relapsed Multiple Myeloma After Previous Transplant
In a UK phase III trial (NCRI Myeloma X Relapse [Intensive] Trial) reported in The Lancet Oncology, Cook et al found that high-dose melphalan plus salvage autologous stem cell transplantation significantly prolonged time to progression vs cyclophosphamide in patients with relapsed multiple myeloma...
Fox Chase Cancer Center Researchers Recommend Updating the Staging Criteria for Breast Cancers With Skin Involvement
Invasive breast cancers with skin involvement, regardless of size or lymph node involvement, are automatically classified as stage III locally advanced tumors, which suggests that they are a relatively serious form of cancer with poor survival. In a study published in the Journal of the American...
Patient Navigation Improves Time to Diagnosis Resolution and Treatment Initiation
In the Patient Navigation Research Program study reported in the Journal of the National Cancer Institute, Freund et al found that a patient navigation intervention improved diagnostic resolution and timely treatment initiation in a clinical population comprising predominantly racial/ethnic...
French Phase III Trial Shows No Benefit of Neoadjuvant Chemoradiation in Stage I and II Esophageal Cancer
The effect of neoadjuvant chemoradiation therapy in early-stage esophageal cancer is not clear. In the phase III FFCD 9901 trial reported in the Journal of Clinical Oncology, Mariette et al found that neoadjuvant chemoradiation including fluorouracil (5-FU) and cisplatin did not improve R0...
Study Identifies Patient and Tumor Characteristics Associated With BRAF and KRAS Mutations in Colon Cancer
In a study in the population of the North Central Cancer Treatment Group (NCCTG)/Alliance N0147 adjuvant trial reported in the Journal of the National Cancer Institute, Gonsalves et al identified patient and tumor characteristics that are associated with KRAS and BRAF V600E mutations in colon...
Frailty Predicts Noninitiation but Not Discontinuation of Adjuvant Hormonal Therapy in Older Women With Breast Cancer
In a study reported in the Journal of Clinical Oncology, Sheppard et al found that frailty was a significant predictor of not starting adjuvant hormonal therapy in breast cancer patients aged ≥ 65 years, but was not predictive of discontinuation of treatment. Study Details The study was...
Adjuvant Paclitaxel Not Equivalent to Doxorubicin/Cyclophosphamide in Breast Cancer With 0 to 3 Positive Axillary Nodes
In the phase III Cancer and Leukemia Group B (CALGB) 40101/Alliance trial reported in the Journal of Clinical Oncology, Shulman et al found that noninferiority of adjuvant single-agent paclitaxel was not established vs doxorubicin/cyclophosphamide for relapse-free survival in women with operable...
ABCA Transporter Gene Expression Is Associated With Poor Outcome in Epithelial Ovarian Cancer
In a study reported in the Journal of the National Cancer Institute, Hedditch et al found that expression of ATP-binding cassette (ABC) transporter genes of the A subfamily (ABCA) had a significant impact on outcome in epithelial ovarian cancer. High ABCA1, Low ABCA5 Expression Analysis of gene...
Study Identifies Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
In a systematic review and meta-analysis reported in the Journal of the National Cancer Institute, Friebel et al attempted to identify factors that appear to modulate risk of breast and ovarian cancer in women who have inherited BRCA1 or BRCA2 mutations. Although the ability to perform...
Abbreviated Screening MRI Protocol Is Highly Accurate in Breast Cancer Detection in Women at Increased Risk
As reported in the Journal of Clinical Oncology, Kuhl et al assessed whether an abbreviated breast magnetic resonance imaging (MRI) protocol, consisting of one pre- and one postcontrast acquisition and derived images—first postcontrast–subtracted (FAST) and maximum-intensity...
Study Shows Annual MRI Plus Mammography May Be Effective Screening Program for Women at High Risk for Breast Cancer
The Ontario Breast Screening Program expanded in July 2011 to include screening of high-risk women aged 30 to 69 years with annual magnetic resonance imaging (MRI) and digital mammography. As reported by Chiarelli et al in Journal of Clinical Oncology, a study of the initial screen in the program...
Multifaceted Intervention Improves Adherence to Annual Colorectal Cancer Screening in Primarily Latino Community Health Centers
Colorectal cancer screening rates are low among Latinos and people living in poverty. In a study reported in JAMA Internal Medicine, Baker et al found that a multifaceted intervention more than doubled adherence to screening with fecal occult blood testing in a largely Latino and uninsured...
Adding Rilotumumab to First-Line Chemotherapy May Benefit Patients With Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Hepatocyte growth factor (HGF) and its receptor MET have been found to promote the proliferation, migration, and survival of tumor cells and to play a role in gastric cancer. In a phase II study reported in The Lancet Oncology, Iveson et al found evidence of benefit from adding the anti-HGF...
Postdiagnosis Calcium and Milk Intake May Be Associated With Improved Overall Survival in Colorectal Cancer Patients
Higher intakes of calcium, vitamin D, and dairy product are associated with lower risk of colorectal cancer, but the effect of such intake on survival in colorectal cancer is unclear. In a study reported in the Journal of Clinical Oncology, Yang et al found that higher postdiagnosis intake of...
Excess Risk of Chronic Late Effects of Treatment in Children With Standard-Risk ALL
Given the changes in treatment of children with acute lymphoblastic leukemia (ALL), the risk of late effects in those treated with current protocols may be different from that in children treated decades ago. In a study of survivors of childhood standard-risk ALL reported in The Lancet Oncology,...
Surgical Treatment for Metastatic Melanoma of the Liver Increases Overall Survival in Select Group of Patients
Surgical resection markedly improved survival among metastatic melanoma patients whose disease is isolated to a few areas in the liver, according to new study findings published in the Journal of the American College of Surgeons. These results mark a departure for melanoma, which is most often...
New Screening Approach Identifies Cancer Mutations in Melanoma That May Lead to More Effective Immunotherapies
Although cancer immunotherapy with adoptive transfer of tumor-infiltrating lymphocytes represents an effective treatment for patients with metastatic melanoma, the antigen targets recognized by these effective tumor-infiltrating lymphocytes remain unclear. According to a new study, a novel...
Phase III Trial Shows Improved Survival With TAS-102 in Metastatic Colorectal Cancer Refractory to Standard Therapies
The new combination agent TAS-102 can improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract O-0022). “Around 50%...
Telephone-Based Intervention Produces Weight Loss in Postmenopausal Women With Breast Cancer Receiving Letrozole
Obesity is associated with poorer outcome in women with operable breast cancer. In the LISA study reported in the Journal of Clinical Oncology, Goodwin et al found that a 24-month telephone-based intervention was effective in reducing body weight in postmenopausal breast cancer patients receiving...
Phase II Trial Shows Improved Progression-Free Survival but Greater Toxicity With Selumetinib vs Chemotherapy in Metastatic Uveal Melanoma
Oncogenic mutations in GNAQ and GNA11, resulting in MAPK pathway activation, are observed in > 80% of uveal melanomas. In a phase II trial reported in JAMA, Carvajal et al found that treatment with the MEK1/MEK2 inhibitor selumetinib significantly prolonged progression-free survival vs...
Immediate Breast Reconstruction After Mastectomy More Likely Among Canadian Women With Higher Income Who Are Treated at Teaching Hospitals
In a study reported in the Journal of Clinical Oncology, Zhong et al assessed factors associated with use of immediate breast reconstruction after treatment or prophylaxis for breast cancer among women in the Canadian universal health-care system. Immediate breast reconstruction was more likely in...
No Benefit of Adding Telomerase Peptide Vaccine to Chemotherapy in Patients With Advanced Pancreatic Cancer
In a UK phase III TeloVac trial reported in The Lancet Oncology, Middleton et al found that the sequential or concurrent addition of the telomerase peptide vaccine GV1001 to gemcitabine/capecitabine did not improve survival in patients with locally advanced or metastatic pancreatic cancer. GV1001...
Uninsured Young Adults Have Poorer Cancer-Specific Outcomes
The Patient Protection and Affordable Care Act is likely to improve insurance coverage for young adults. In a study reported in the Journal of Clinical Oncology, Aizer et al examined the association between insurance status and cancer outcomes among young adults, finding that the uninsured...
HPV-Positive Disease Predicts Longer Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma
Patients with human papillomavirus (HPV)-positive oropharyngeal cancer have reduced risk of progression compared with those with HPV-negative disease, but the effect of HPV status on overall survival after progression has not been clear. In a study reported in the Journal of Clinical Oncology,...
Adding Novel Agent to Standard Therapy Improves Survival in Patients With Pancreatic Cancer After Prior Gemcitabine-Based Therapy
The addition of the novel agent MM-398 to standard treatment improved overall survival in patients with metastatic pancreatic cancer who have already received gemcitabine, according to a phase III trial reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract...
FDA Advisory Committee Votes Against Accelerated Approval for Olaparib in Ovarian Cancer
The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have...
No Disease-Free Survival Benefit of Adding Cetuximab to FOLFOX4 in KRAS Exon 2 Wild-Type Resected Stage III Colon Cancer
In an interim analysis of the European phase III PETACC-8 trial reported in The Lancet Oncology, Taieb et al found no disease-free survival or overall survival benefit with the addition of cetuximab (Erbitux) to standard adjuvant FOLFOX4 (oxaliplatin, fluorouracil, leucovorin) therapy in patients...
Daily Low-Dose Aspirin Use May Reduce Risk of Developing Pancreatic Cancer
Men and women who took low-dose aspirin regularly had a 48% reduction in their risk of developing pancreatic cancer, according to a new study. In addition, the longer a person started taking low-dose aspirin, the greater the benefit, ranging from 48% reduction in people who started 3 years before...
No Overall Survival Improvement but Some Palliative Benefit With Gefitinib vs Placebo in Esophageal Cancer Progressing After Chemotherapy
In what may be the first randomized trial of systemic therapy in this setting, Dutton and colleagues evaluated gefitinib (Iressa) vs placebo in patients with esophageal cancer progressing after chemotherapy. As reported in The Lancet Oncology, the COG trial showed no survival benefit with gefitinib ...
Oncologist Communication Skills Training Program Effective for Both Oncologists and Patients
In a Japanese study reported in the Journal of Clinical Oncology, Fujimori et al found that an oncologist communication skills training program based on patient preferences in receiving bad news was of benefit to both oncologists and patients. Study Details In the study, 30 oncologists were...
Tumor Microenvironment of Metastasis Score Independently Predicts Distant Metastasis in Estrogen Receptor–Positive/HER2-Negative Breast Cancer
Tumor microenvironment of metastasis (TMEM) consists of direct contact between a macrophage, an endothelial cell, and a tumor cell. In a case-control study reported in the Journal of the National Cancer Institute, Rohan et al found that TMEM score was an independent predictor of distant metastasis...
Adding Antiangiopoietin Agent Trebananib to Paclitaxel Improves Progression-Free Survival in Recurrent Epithelial Ovarian Cancer
Trebananib inhibits angiogenesis by blocking the binding of angiopoietins 1 and 2 to the Tie2 receptor expressed on endothelial cells, a mechanism that differs from VEGF inhibitors and that involves a different signaling pathway. In the phase III TRINOVA-1 trial reported in The Lancet Oncology,...
Combining Multiple Imaging Approaches Can Better Distinguish Malignant and Benign Breast Tumors and Reduce Unnecessary Biopsies
A new study found that an imaging technique called multiparametric 18fluorodeoxyglucose positron-emission tomography magnetic resonance imaging (18FDG PET-MRI), which combines four imaging approaches, can better distinguish malignant breast tumors from those that are benign, compared with imaging...
New Tool Predicts Financial Pain for Cancer Patients
In an online report in the journal Cancer, a team of University of Chicago cancer specialists have described the first tool—11 questions, assembled and refined from conversations with more than 150 patients with advanced cancer—to measure a patient’s risk for, and ability to...
No Improvement in Long-Term Outcomes With Extended Colectomy for Sporadic Colorectal Cancer in Patients Younger Than Age 50
Extended colectomy in patients with sporadic colorectal cancer who were younger than age 50, in comparison with segmental resection, did not improve the risk of tumor recurrence or disease-free survival, according to the results of a retrospective study presented by Klos et al in the Journal of...
HERA Trial 8-Year Follow-up Shows Low Rate of Trastuzumab-Associated Cardiac Dysfunction
In a study reported in Journal of Clinical Oncology, Azambuja et al found low rates of trastuzumab (Herceptin)-related cardiac dysfunction over a median of 8 years of follow-up in the HERceptin Adjuvant (HERA) trial. The majority of patients with cardiac dysfunction achieved acute recovery. Study...
EPIC Cohort Study: High Thyroglobulin and Low TSH Precede Differentiated Thyroid Cancer, but Neither Can Be Used in Screening
In a study of the association of thyroid-stimulating hormone (TSH), thyroglobulin, and thyroid hormones with risk of differentiated thyroid cancer reported in Journal of the National Cancer Institute, Rinaldi et al found that high thyroglobulin levels can precede thyroid cancer by many years and...
Development of Orteronel for Prostate Cancer Voluntarily Discontinued by Takeda
Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700), an investigational oral, nonsteroidal, selective inhibitor of 17,20-lyase, for prostate cancer. The decision follows the results of two phase III...
Racial Disparities in Sentinel Lymph Node Biopsy in Women With Breast Cancer
A study by Black et al from The University of Texas MD Anderson Cancer Center, Houston, found that the use of sentinel lymph node biopsy to stage early breast cancer increased in both black and white women from 2002 to 2007, but the rates remained lower in black than white patients, a disparity...
Diversity of Intestinal Tract Bacteria Associated With Mortality Outcomes After Stem Cell Transplant, Study Shows
New research published online in Blood suggests that the diversity of bacteria in the gastrointestinal tract of patients receiving stem cell transplants may be an important predictor of their post-transplant survival. Potential Connections Previous studies have shown that the intensive treatment...
Surgical Treatment Delay May Not Result in Worse Outcomes in Patients With Colon Cancer
A “reasonable” delay prior to surgery for colon cancer may not result in worse outcomes, according to the results of a retrospective study presented by Amri et al in the Annals of Surgical Oncology. Flexibility in scheduling surgery may lead to an improvement in the quality and safety...
Similar Survival Rates, Less Toxicity Reported With Reduced-Intensity vs Myeloablative Total-Body Irradiation Before Transplant in Acute Leukemia
Used as a conditioning regimen for allogeneic transplantation in patients with acute leukemia, reduced-intensity total-body irradiation yielded similar overall and relapse-free survival rates to those seen with myeloablative total-body irradiation but with shorter hospital stays and fewer intensive ...
Glioma-Associated Antigen Peptide Vaccination Produces Antigen-Specific T-Cell Response and Clinical Activity in Children With High-Grade Gliomas
In a study reported in the Journal of Clinical Oncology, Pollack et al found antigen-specific immune responses and evidence of clinical activity with glioma-associated antigen (GAA) peptide vaccination in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. Study Details In ...
Combined Index Predicts Early Multiple Myeloma Progression-Related Death in Patients Receiving Front-Line Autologous Stem Cell Transplantation
In a European study reported in the Journal of Clinical Oncology, Moreau et al developed and validated a combined index for prognosis in patients with multiple myeloma treated with front-line autologous stem cell transplantation. The index, consisting of high lactate dehydrogenase (LDH) level,...
Study Reveals Long-Term Benefits With Prone Hypofractionated Radiation Therapy and a Concurrent Boost in Early-Stage Breast Cancer
Prone accelerated intensity-modulated radiation therapy with a concomitant boost produced excellent local tumor control and cosmesis while sparing normal tissues in women with early-stage breast cancer, according to the 5-year study results reported by Osa et al in the International Journal of...
Priming Pancreatic Cancer Cells With a Vaccine May Allow Them to Respond to Immunotherapy
Pancreatic ductal adenocarcinoma is considered a “nonimmunogenic” neoplasm and does not typically respond to immunotherapy, in part due to a complex tumor microenvironment that provides a formidable barrier to immune infiltration and function. A new study by Lutz et al has found that by ...
